• Multivariate Analysis of RNA C...

*Result*: Multivariate Analysis of RNA Chemistry Marks Uncovers Epitranscriptomics-Based Biomarker Signature for Adult Diffuse Glioma Diagnostics.

Title:
Multivariate Analysis of RNA Chemistry Marks Uncovers Epitranscriptomics-Based Biomarker Signature for Adult Diffuse Glioma Diagnostics.
Authors:
Relier S; IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, Hérault 34094, France., Amalric A; IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, Hérault 34094, France.; IRMB-PPC, INM, Univ Montpellier, CHU Montpellier, INSERM CNRS, Montpellier 34295, France., Attina A; IRMB-PPC, INM, Univ Montpellier, CHU Montpellier, INSERM CNRS, Montpellier 34295, France., Koumare IB; Neurosurgery Department, Montpellier University Medical Center, Montpellier, Hérault 34295, France.; Neurosurgery Department, CHU Gabriel Toure, Bamako, Mali., Rigau V; Department of Pathology and Oncobiology, Montpellier University Medical Center, Montpellier, Hérault 34295, France., Burel Vandenbos F; Central Laboratory of Pathology, Univ. Côte d'Azur, CHU Nice, CNRS, INSERM, Nice, Alpes-Maritimes 06000, France., Fontaine D; Neurosurgery Department, Univ. Côte d'Azur, CHU Nice, Nice, Alpes-Maritimes 06000, France., Baroncini M; Neurosurgery Department, CHU Lille, Univ. of Lille, Lille, Nord 59037, France., Hugnot JP; IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, Hérault 34094, France., Duffau H; IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, Hérault 34094, France.; Neurosurgery Department, Montpellier University Medical Center, Montpellier, Hérault 34295, France., Bauchet L; IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, Hérault 34094, France.; Neurosurgery Department, Montpellier University Medical Center, Montpellier, Hérault 34295, France., Hirtz C; IRMB-PPC, INM, Univ Montpellier, CHU Montpellier, INSERM CNRS, Montpellier 34295, France., Rivals E; LIRMM, Univ. Montpellier, CNRS, Montpellier, Hérault 34095, France., David A; IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, Hérault 34094, France.; IRMB-PPC, INM, Univ Montpellier, CHU Montpellier, INSERM CNRS, Montpellier 34295, France.
Source:
Analytical chemistry [Anal Chem] 2022 Sep 06; Vol. 94 (35), pp. 11967-11972. Date of Electronic Publication: 2022 Aug 23.
Publication Type:
Journal Article; Research Support, Non-U.S. Gov't
Language:
English
Journal Info:
Publisher: American Chemical Society Country of Publication: United States NLM ID: 0370536 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-6882 (Electronic) Linking ISSN: 00032700 NLM ISO Abbreviation: Anal Chem Subsets: MEDLINE
Imprint Name(s):
Original Publication: Washington, American Chemical Society.
MeSH Terms:
Glioma*/diagnosis , Glioma*/genetics , RNA*, Metabolomics/methods ; Proteomics/methods ; Biomarkers ; Humans ; Multivariate Analysis
References:
Aging (Albany NY). 2019 Feb 27;11(4):1204-1225. (PMID: 30810537)
Oncogene. 2016 Apr 7;35(14):1785-96. (PMID: 26234676)
Ann Surg. 2012 Apr;255(4):720-30. (PMID: 22395091)
Glia. 2013 Feb;61(2):225-39. (PMID: 23047160)
Int J Cancer. 2012 May 1;130(9):2077-87. (PMID: 21671476)
J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94. (PMID: 17021403)
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. (PMID: 34185076)
Nat Commun. 2021 Mar 19;12(1):1716. (PMID: 33741917)
Cancer Cell. 2017 May 8;31(5):619-620. (PMID: 28486104)
Int J Mol Sci. 2021 Nov 01;22(21):. (PMID: 34769301)
Mol Brain. 2021 Jul 19;14(1):119. (PMID: 34281602)
Cell Res. 2018 Apr;28(4):395-404. (PMID: 29463900)
Acta Neuropathol. 2009 Oct;118(4):469-74. (PMID: 19554337)
Bioinformation. 2017 Jun 30;13(6):202-208. (PMID: 28729763)
Clin Chim Acta. 2014 Jan 20;428:57-62. (PMID: 24177150)
PLoS One. 2013 Jun 21;8(6):e66574. (PMID: 23805239)
Anticancer Res. 2018 Nov;38(11):6113-6119. (PMID: 30396926)
Crit Rev Clin Lab Sci. 2022 Jan;59(1):1-18. (PMID: 34473579)
Science. 2013 May 17;340(6134):857-61. (PMID: 23539183)
Brief Bioinform. 2019 May 21;20(3):952-975. (PMID: 29194464)
Med Oncol. 2016 Dec;33(12):133. (PMID: 27807722)
Oncotarget. 2015 Oct 6;6(30):30232-8. (PMID: 26338964)
Cancers (Basel). 2020 Mar 20;12(3):. (PMID: 32244981)
Acta Neuropathol. 2007 Aug;114(2):97-109. (PMID: 17618441)
PLoS Comput Biol. 2016 Jul 11;12(7):e1004977. (PMID: 27400279)
Front Oncol. 2021 Jan 21;10:615400. (PMID: 33552990)
Neurology. 2020 Feb 25;94(8):e830-e841. (PMID: 31969465)
Curr Opin Neurol. 2017 Dec;30(6):643-649. (PMID: 28901970)
Metabolites. 2021 Jan 30;11(2):. (PMID: 33573224)
Virchows Arch. 2015 Apr;466(4):433-44. (PMID: 25861023)
Nat Rev Cancer. 2020 Jun;20(6):303-322. (PMID: 32300195)
Nucleic Acids Res. 2022 May 6;50(8):4201-4215. (PMID: 34850949)
Biomarkers. 2016 Nov;21(7):578-88. (PMID: 27133288)
PLoS One. 2013 Dec 19;8(12):e81701. (PMID: 24367489)
Substance Nomenclature:
0 (Biomarkers)
63231-63-0 (RNA)
Entry Date(s):
Date Created: 20220823 Date Completed: 20220908 Latest Revision: 20250728
Update Code:
20260130
PubMed Central ID:
PMC9453740
DOI:
10.1021/acs.analchem.2c01526
PMID:
35998076
Database:
MEDLINE

*Further Information*

*One of the main challenges in cancer management relates to the discovery of reliable biomarkers, which could guide decision-making and predict treatment outcome. In particular, the rise and democratization of high-throughput molecular profiling technologies bolstered the discovery of "biomarker signatures" that could maximize the prediction performance. Such an approach was largely employed from diverse OMICs data (i.e., genomics, transcriptomics, proteomics, metabolomics) but not from epitranscriptomics, which encompasses more than 100 biochemical modifications driving the post-transcriptional fate of RNA: stability, splicing, storage, and translation. We and others have studied chemical marks in isolation and associated them with cancer evolution, adaptation, as well as the response to conventional therapy. In this study, we have designed a unique pipeline combining multiplex analysis of the epitranscriptomic landscape by high-performance liquid chromatography coupled to tandem mass spectrometry with statistical multivariate analysis and machine learning approaches in order to identify biomarker signatures that could guide precision medicine and improve disease diagnosis. We applied this approach to analyze a cohort of adult diffuse glioma patients and demonstrate the existence of an "epitranscriptomics-based signature" that permits glioma grades to be discriminated and predicted with unmet accuracy. This study demonstrates that epitranscriptomics (co)evolves along cancer progression and opens new prospects in the field of omics molecular profiling and personalized medicine.*